Artwork

Flot.bio์—์„œ ์ œ๊ณตํ•˜๋Š” ์ฝ˜ํ…์ธ ์ž…๋‹ˆ๋‹ค. ์—ํ”ผ์†Œ๋“œ, ๊ทธ๋ž˜ํ”ฝ, ํŒŸ์บ์ŠคํŠธ ์„ค๋ช…์„ ํฌํ•จํ•œ ๋ชจ๋“  ํŒŸ์บ์ŠคํŠธ ์ฝ˜ํ…์ธ ๋Š” Flot.bio ๋˜๋Š” ํ•ด๋‹น ํŒŸ์บ์ŠคํŠธ ํ”Œ๋žซํผ ํŒŒํŠธ๋„ˆ๊ฐ€ ์ง์ ‘ ์—…๋กœ๋“œํ•˜๊ณ  ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. ๋ˆ„๊ตฐ๊ฐ€๊ฐ€ ๊ท€ํ•˜์˜ ํ—ˆ๋ฝ ์—†์ด ๊ท€ํ•˜์˜ ์ €์ž‘๋ฌผ์„ ์‚ฌ์šฉํ•˜๊ณ  ์žˆ๋‹ค๊ณ  ์ƒ๊ฐ๋˜๋Š” ๊ฒฝ์šฐ ์—ฌ๊ธฐ์— ์„ค๋ช…๋œ ์ ˆ์ฐจ๋ฅผ ๋”ฐ๋ฅด์‹ค ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค https://ko.player.fm/legal.
Player FM -ํŒŸ ์บ์ŠคํŠธ ์•ฑ
Player FM ์•ฑ์œผ๋กœ ์˜คํ”„๋ผ์ธ์œผ๋กœ ์ „ํ™˜ํ•˜์„ธ์š”!

Bahija Jallal, Immunocore ๐Ÿ‡ฌ๐Ÿ‡ง | Commercial, Diversity, and AI | E14

1:15:45
 
๊ณต์œ 
 

Manage episode 409010244 series 3470295
Flot.bio์—์„œ ์ œ๊ณตํ•˜๋Š” ์ฝ˜ํ…์ธ ์ž…๋‹ˆ๋‹ค. ์—ํ”ผ์†Œ๋“œ, ๊ทธ๋ž˜ํ”ฝ, ํŒŸ์บ์ŠคํŠธ ์„ค๋ช…์„ ํฌํ•จํ•œ ๋ชจ๋“  ํŒŸ์บ์ŠคํŠธ ์ฝ˜ํ…์ธ ๋Š” Flot.bio ๋˜๋Š” ํ•ด๋‹น ํŒŸ์บ์ŠคํŠธ ํ”Œ๋žซํผ ํŒŒํŠธ๋„ˆ๊ฐ€ ์ง์ ‘ ์—…๋กœ๋“œํ•˜๊ณ  ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. ๋ˆ„๊ตฐ๊ฐ€๊ฐ€ ๊ท€ํ•˜์˜ ํ—ˆ๋ฝ ์—†์ด ๊ท€ํ•˜์˜ ์ €์ž‘๋ฌผ์„ ์‚ฌ์šฉํ•˜๊ณ  ์žˆ๋‹ค๊ณ  ์ƒ๊ฐ๋˜๋Š” ๊ฒฝ์šฐ ์—ฌ๊ธฐ์— ์„ค๋ช…๋œ ์ ˆ์ฐจ๋ฅผ ๋”ฐ๋ฅด์‹ค ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค https://ko.player.fm/legal.

Weโ€™re super privileged to chat online with Bahija Jallal, the CEO of Immunocore. Immunocore is the largest biotech in the UK and the 5th largest in Europe with a market cap of just over 3 billion dollars. We talk about how Immunocore has helped thousands of cancer patients and has become a commercial biotech. We also talk about why she thinks gender and race diversity are a business case and how AI is changing protein and biologics engineering. ๐Ÿ’Ž ABOUT THE SPEAKER Iโ€™ve โ€œknownโ€ Bahija for over 10 years, after reading her profile in a student pharma magazine when I was studying bioengineering in France. At that time, she was head of MedImmune and SVP R&D at AstraZeneca. Now as the CEO of Immunocore, with their pioneering T cell receptor platform, she has helped to bring incredible treatments for cancer patients to market. ๐Ÿ”— LINKS MENTIONED - Bahija on the Breakthrough Labs podcast - https://open.spotify.com/episode/2X4xedUdJid9GeioRSkCrP?si=39d8c7511aab443f - Immatics builds on its PRAME Success (and competes with Immunocore) - [OncologyPipeline.com](https://www.oncologypipeline.com/apexonco/immatics-builds-its-prame-success) ๐Ÿ“œ TRANSCRIPT Read the full transcript here: ๐Ÿซถ FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio ๐ŸŽ™๏ธ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. โญ๏ธ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! ๐Ÿ™ LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. โฐ TIMESTAMPS

[00:00:00] Intro

[00:00:34] Welcome

[00:01:46] Immunocoreโ€™s life-changing cancer drug

[00:07:40] Commercializing Immunocore

[00:13:46] Explaining the TCR technology

[00:20:40] Targeting tumors with PRAME

[00:23:26] Immunocore now and then

[00:35:37] Why Bahija chose Immunocore

[00:40:22] Top lessons from Bahija Jallal

[00:45:48] How is risk appetite connected to innovation?

[00:49:10] Diversity in biotech

[01:00:59] Biological innovation

[01:05:49] AI in protein engineering optimization

[01:14:42] Thanks for listening

  continue reading

21 ์—ํ”ผ์†Œ๋“œ

Artwork
icon๊ณต์œ 
 
Manage episode 409010244 series 3470295
Flot.bio์—์„œ ์ œ๊ณตํ•˜๋Š” ์ฝ˜ํ…์ธ ์ž…๋‹ˆ๋‹ค. ์—ํ”ผ์†Œ๋“œ, ๊ทธ๋ž˜ํ”ฝ, ํŒŸ์บ์ŠคํŠธ ์„ค๋ช…์„ ํฌํ•จํ•œ ๋ชจ๋“  ํŒŸ์บ์ŠคํŠธ ์ฝ˜ํ…์ธ ๋Š” Flot.bio ๋˜๋Š” ํ•ด๋‹น ํŒŸ์บ์ŠคํŠธ ํ”Œ๋žซํผ ํŒŒํŠธ๋„ˆ๊ฐ€ ์ง์ ‘ ์—…๋กœ๋“œํ•˜๊ณ  ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. ๋ˆ„๊ตฐ๊ฐ€๊ฐ€ ๊ท€ํ•˜์˜ ํ—ˆ๋ฝ ์—†์ด ๊ท€ํ•˜์˜ ์ €์ž‘๋ฌผ์„ ์‚ฌ์šฉํ•˜๊ณ  ์žˆ๋‹ค๊ณ  ์ƒ๊ฐ๋˜๋Š” ๊ฒฝ์šฐ ์—ฌ๊ธฐ์— ์„ค๋ช…๋œ ์ ˆ์ฐจ๋ฅผ ๋”ฐ๋ฅด์‹ค ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค https://ko.player.fm/legal.

Weโ€™re super privileged to chat online with Bahija Jallal, the CEO of Immunocore. Immunocore is the largest biotech in the UK and the 5th largest in Europe with a market cap of just over 3 billion dollars. We talk about how Immunocore has helped thousands of cancer patients and has become a commercial biotech. We also talk about why she thinks gender and race diversity are a business case and how AI is changing protein and biologics engineering. ๐Ÿ’Ž ABOUT THE SPEAKER Iโ€™ve โ€œknownโ€ Bahija for over 10 years, after reading her profile in a student pharma magazine when I was studying bioengineering in France. At that time, she was head of MedImmune and SVP R&D at AstraZeneca. Now as the CEO of Immunocore, with their pioneering T cell receptor platform, she has helped to bring incredible treatments for cancer patients to market. ๐Ÿ”— LINKS MENTIONED - Bahija on the Breakthrough Labs podcast - https://open.spotify.com/episode/2X4xedUdJid9GeioRSkCrP?si=39d8c7511aab443f - Immatics builds on its PRAME Success (and competes with Immunocore) - [OncologyPipeline.com](https://www.oncologypipeline.com/apexonco/immatics-builds-its-prame-success) ๐Ÿ“œ TRANSCRIPT Read the full transcript here: ๐Ÿซถ FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio ๐ŸŽ™๏ธ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. โญ๏ธ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! ๐Ÿ™ LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. โฐ TIMESTAMPS

[00:00:00] Intro

[00:00:34] Welcome

[00:01:46] Immunocoreโ€™s life-changing cancer drug

[00:07:40] Commercializing Immunocore

[00:13:46] Explaining the TCR technology

[00:20:40] Targeting tumors with PRAME

[00:23:26] Immunocore now and then

[00:35:37] Why Bahija chose Immunocore

[00:40:22] Top lessons from Bahija Jallal

[00:45:48] How is risk appetite connected to innovation?

[00:49:10] Diversity in biotech

[01:00:59] Biological innovation

[01:05:49] AI in protein engineering optimization

[01:14:42] Thanks for listening

  continue reading

21 ์—ํ”ผ์†Œ๋“œ

Tous les รฉpisodes

×
 
Loading …

ํ”Œ๋ ˆ์ด์–ด FM์— ์˜ค์‹ ๊ฒƒ์„ ํ™˜์˜ํ•ฉ๋‹ˆ๋‹ค!

ํ”Œ๋ ˆ์ด์–ด FM์€ ์›น์—์„œ ๊ณ ํ’ˆ์งˆ ํŒŸ์บ์ŠคํŠธ๋ฅผ ๊ฒ€์ƒ‰ํ•˜์—ฌ ์ง€๊ธˆ ๋ฐ”๋กœ ์ฆ๊ธธ ์ˆ˜ ์žˆ๋„๋ก ํ•ฉ๋‹ˆ๋‹ค. ์ตœ๊ณ ์˜ ํŒŸ์บ์ŠคํŠธ ์•ฑ์ด๋ฉฐ Android, iPhone ๋ฐ ์›น์—์„œ๋„ ์ž‘๋™ํ•ฉ๋‹ˆ๋‹ค. ์žฅ์น˜ ๊ฐ„ ๊ตฌ๋… ๋™๊ธฐํ™”๋ฅผ ์œ„ํ•ด ๊ฐ€์ž…ํ•˜์„ธ์š”.

 

๋น ๋ฅธ ์ฐธ์กฐ ๊ฐ€์ด๋“œ